Market attractiveness remains robust as the global demand for traditional Chinese medicinal ingredients accelerates, driven by rising consumer health consciousness and aging populations. The competitive intensity is moderate; a handful of legacy producers dominate pricing, yet new entrants are leveraging niche formulations and premium branding to erode market share. Our long‑term outlook is positive, with CAGR projections of 7‑9 % through 2035, supported by expanding distribution channels and regulatory endorsement of quality standards. The innovation landscape is vibrant, highlighted by biotechnological extraction methods, value‑added nutraceutical blends, and digital traceability platforms that enhance product safety. On the demand–supply balance, supply growth is keeping pace with demand, but occasional raw‑material shortages—particularly high‑grade donkey hide—create localized price volatility. Key risk factors include tightening animal‑welfare regulations, potential trade barriers, and fluctuations in raw‑material costs, all of which could compress margins if not proactively managed. This assessment underpins the Ejiao Health Products market outlook for strategic investors.